If clinical trials were a treasure hunt (and some days, they certainly feel like one), then finding the right patients is the map, the compass, and occasionally the buried chest itself. In ophthalmology, where the nuances of disease can live quietly within an image or hide behind subtle symptoms, patient identification is both critical and, at times, delightfully complicated. Enter artificial intelligence: equal parts detective, librarian, and speed-reader, now stepping into the clinical trial world with a promise to make that treasure hunt a little less… puzzling.
Let’s start with prescreening, where AI is already beginning to shine (and perhaps squint just a little less than the rest of us). In retina-focused trials, for example, vast databases of imaging including OCT scans, fundus photos, widefield images hold a wealth of patient information waiting to be unlocked. Traditionally, reviewing these images for eligibility required time, expertise, and a fair bit of patience. AI, however, can rapidly analyze these datasets, identifying patients whose anatomical features align with inclusion criteria, whether that’s a specific lesion size, retinal thickness, or pattern of disease progression. The result? A curated pool of high-probability candidates and a meaningful reduction in screen failures. In other words, fewer needles in haystacks, and more haystacks that have already been thoughtfully sorted.
But why stop at images? AI is equally adept at sifting through patient databases, matching real-world clinical data against complex inclusion and exclusion criteria with remarkable speed. Protocols that once required manual database review, with spreadsheets, EHR dives, and late-night cross-checking, can now be parsed algorithmically, flagging eligible patients across sites in a fraction of the time. This doesn’t just accelerate recruitment; it fundamentally reshapes it. Instead of reactively searching for patients when a trial opens, sites can proactively identify and engage potential participants earlier, creating a smoother, more efficient path to enrollment.
And then, just when you think AI might settle into a quiet supporting role, it pops back up as an exploratory endpoint pioneer. Advanced image analysis, pattern recognition, and machine learning models are opening new doors in how we quantify disease and measure response. Subtle changes, once difficult to capture consistently, can now be tracked with greater precision and objectivity. AI-driven endpoints hold the potential to complement traditional clinical measures, offering deeper insight into therapeutic impact and, perhaps, revealing treatment effects that might otherwise go unnoticed. It’s like adjusting the focus on a microscope and discovering there was more to see all along.
Of course, even the most brilliant algorithm benefits from good company. The real magic happens when these technological advances are paired with strong site relationships and experienced clinical teams. Sites that know their patient populations, understand protocol nuances, and collaborate closely with sponsors can use AI insights to act quickly and effectively. Together, this combination of human expertise plus machine efficiency can significantly reduce trial timelines, lower operational costs, and improve overall study performance. Faster recruitment, fewer screen failures, streamlined workflows — it all adds up to trials that move with purpose and precision.
At Ora, we see AI not as a replacement for the human side of clinical research, but as an amplifier of it. A tool that helps us ask better questions, find better answers, and ultimately design trials that are smarter from the start. Because when you bring together advanced technology, thoughtful design, and a connected clinical community, you don’t just make trials faster, you make them better. Eye think… that’s a future worth seeing clearly.